k | n | Prevalence | 95% CI | Q | p Value | I^{2} (%) | 95%CI | ||
---|---|---|---|---|---|---|---|---|---|

Point studies | FE model | 12 | 2975 | 9.6% | 8.5% to 10.7% | ||||

RE model | 12 | 2975 | 11.5% | 6.6% to 17.4% | 182.1 | <0.001 | 94.0% | 91.2% to 95.9% | |

RE model without outliers | 11 | 2467 | 12.9% | 8.2% to 18.6% | 84.1 | <0.001 | 88.1% | 80.7% to 92.7% | |

RE in subgroup analysis 1 | 11 | 2785 | 11.6% | 6.2% to 18.3% | 183.4 | <0.001 | 94.5% | 92.0% to 96.3% | |

RE in subgroup analysis 2 | 12 | 2212 | 11.1% | 6.2% to 17.1% | 170.1 | <0.001 | 93.5% | 90.5% to 95.6% | |

Subgroup analysis 1: without Simon et al12 and Taman and Ozpoyraz40Subgroup analysis 2: with BD-I subsample in Simon et al12 and without BD-II subsample in Simon et al,12 BD-II subsample in Chang et al (2012) and Otto et al (2006) | |||||||||

Lifetime studies | FE model | 18 | 4919 | 15.8% | 14.8% to 16.9% | ||||

RE model | 18 | 4919 | 15.1% | 9.7% to 21.5% | 318.3 | <0.001 | 94.7% | 92.8% to 96.0% | |

RE in subgroup analysis 1 | 8 | 3411 | 20.1% | 12.7% to 28.7% | 48.8 | <0.001 | 85.7% | 73.7% to 92.2% | |

RE in subgroup analysis 2 | 13 | 1616 | 12.5% | 6.4% to 20.1% | 122.3 | <0.001 | 90.2% | 85.1% to 93.6% | |

RE in subgroup analysis 3 | 11 | 1603 | 11.2% | 5.0% to 19.4% | 110.8 | <0.001 | 91.0% | 85.9% to 94.2% | |

k=number of included studies n=number of patients in the included studies Subgroup analysis 1: with BD-I samples only Subgroup analysis 2: with BD-II and mixed samples Subgroup analysis 3: with mixed samples only |

BD, bipolar disorder; FE, fixed-effects model; GAD, generalised anxiety disorders;

RE, random-effects model with Bayesian estimator.